Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 24 · below the Ichimoku cloud · RSI 40 · MACD below its signal
None of the 29 investors followed here reported a position in MIRA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MIRA trade in the reports read so far (1,238 of 1,240; the rest are being read now).
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 15, 2025 | Aminov ErezChief Executive Officer | Sale at price 2.11 per share. | 613.6K | $1.29M |
| Oct 15, 2025 | Aminov ErezChief Executive Officer | Conversion of Exercise of derivative security at price 0.84 - 1.16 per share. | 613.6K | $590.49K |
| Sep 30, 2025 | Aminov ErezChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 2.69M | — |
| Sep 30, 2025 | Shekhat Denil NanjiDirector | Stock Award(Grant) at price 1.35 per share. | 22.4K | $30.21K |
| Aug 28, 2025 | Aminov ErezChief Executive Officer | Stock Award(Grant) at price 1.37 per share. | 62.5K | $85.63K |
| Mar 25, 2025 | Aminov ErezChief Executive Officer | Stock Award(Grant) at price 1.15 per share. | 125K | $143.75K |
| Nov 19, 2024 | Aminov ErezChief Executive Officer | Sale at price 1.27 - 1.39 per share. | 100K | $133.65K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.9 | 2.4 | -15.7 | -1.9 | 1.0 | -10.7 | -16.4 | -2.8 | 9.7 | -19.3 | −54.8% | ||
| 2025 | 5.3 | -16.7 | -2.0 | 18.4 | 16.4 | -10.4 | 36.4 | -17.0 | -0.7 | 22.8 | -11.4 | 2.0 | +32.5% |
| 2024 | -10.5 | 6.9 | 9.5 | -22.7 | -3.8 | -22.1 | 229.7 | -8.1 | -32.6 | 68.5 | -41.1 | -11.6 | +8.6% |
| 2023 | -25.9 | -58.3 | 83.0 | -70.4 | −83.3% |
Buy / hold / sell counts
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.